Biotech Values

[semi_infinite]

Sure if you go by ITT. As noted by John Day in his blog, many in the drug only arm had to cross over to ablation to get their condition cured or managed ( but still counted as being in the drug arm). And a portion of the ablation arm was not ablated and remained on meds because they were found to be inappropriate candidates after randomization (those were still counted in the ablation arm under ITT). There was criticism of those issues happening when the trial protocol was set up.

Wait for the final analysis to be published by one of the major journals. Likely the ACC.